Syndax Pharmaceuticals Reports $64.9 Million in Quarterly Revenues, Driven by Revuforj Sales

Syndax Pharmaceuticals, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenues reaching $64.9 million for the three months ended March 31, 2026, compared to $20.0 million in the same period last year. This increase was primarily driven by a substantial rise in product revenue from its FDA-approved drug Revuforj, which generated $48.9 million, marking a 144% increase year-over-year. Additionally, the company recognized $15.9 million in collaboration revenue related to its partnership with Incyte for the commercialization of Niktimvo, which was not yet generating revenue in the prior year.

The company’s operating expenses decreased to $99.1 million from $103.8 million in the previous year, reflecting a reduction in research and development costs and selling, general, and administrative expenses. Notably, the loss from operations improved significantly to $34.2 million from $83.8 million year-over-year. The net loss for the quarter was $42.7 million, a decrease from $84.8 million in the same quarter of 2025, indicating a positive trend in financial performance.

Syndax has also made strategic advancements, including the successful launch of Revuforj and the continued commercialization of Niktimvo, which received FDA approval in August 2024. The company reported a 160% increase in total prescriptions for Revuforj compared to the first quarter of 2025, and it anticipates further growth as more patients proceed to hematopoietic stem cell transplants after treatment. The company is actively pursuing additional clinical trials and data presentations throughout 2026 to support its product lines.

Operationally, Syndax's cash, cash equivalents, and short-term investments totaled $352.1 million as of March 31, 2026, down from $529.7 million at the end of 2025. The decrease in cash reserves is attributed to ongoing operational expenses, although the company reported a reduction in net cash used in operating activities from $95.2 million to $50.3 million year-over-year. The company’s employee headcount remains stable, supporting its ongoing clinical and commercial activities.

Looking ahead, Syndax aims to leverage its current cash position and product revenues to fund future growth and development. The company plans to continue its focus on research and development, particularly for its existing product candidates, while also exploring potential collaborations and licensing opportunities to expand its pipeline. Despite the challenges inherent in the biopharmaceutical industry, Syndax remains optimistic about its trajectory and the potential for future profitability.